Skip to content

The Impact of Sugammadex Dose Optimization (TOFR >=0.95) Versus Neostigmine on Postoperative Pulmonary Complications in Elderly Patients Undergoing Laparoscopic Colorectal Surgery

The Impact of Sugammadex Dose Optimization (TOFR >=0.95) Versus Neostigmine on Postoperative Pulmonary Complications in Elderly Patients Undergoing Laparoscopic Colorectal Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104158
Enrollment
Unknown
Registered
2025-06-12
Start date
2025-06-30
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal malignant tumor

Interventions

Sugammadex group:After the surgery, when T2 is reproduced, Shu Geng Glucose Sodium is given
Neostigmine group:After the surgery, when T2 was reproduced, the maximum dose of neostigmine was 50ug/kg and atropine was 20ug/kg. The maximum dose of neostigmine did not exceed 5mg. When the calculat

Sponsors

Nanjing Drum Tower Hospital Group Suqian Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients aged 65 to 80 who are scheduled for laparoscopic colorectal surgery; (2) ASA classification levels I-III; (3)18.5 <=BMI< 28 kg/m 2; (4) Agree to participate in this experiment and sign the informed consent form

Exclusion criteria

Exclusion criteria: (1) Patients with expected difficult airways; (2) Patients with known or suspected neuromuscular diseases (such as myasthenia gravis, periodic paralysis, or polymyositis); (3) Diabetes patients with peripheral neuropathy; (4) Patients with a history of malignant hyperthermia or family history; (5) Patients taking anticonvulsants, magnesium, or certain antibiotics (such as gentamicin, neomycin, polymyxin, paromycin, etc.) known to interact with neuromuscular blocking agents; (6) Patients with severe liver and kidney dysfunction (ALT or AST exceeding the upper limit of normal values by more than twice, GFR<30 mL/min); (7) Patients with cardiac dysfunction (NYHA = 3), bradycardia, and ventricular tachycardia; (8) Patients who are allergic to research drugs or anesthetics; (9) Patients who have participated in other clinical studies within the past 30 days.

Design outcomes

Primary

MeasureTime frame
Postoperative pulmonary complications;

Secondary

MeasureTime frame
Incidence of residual neuromuscular blockade;The incidence of postoperative nausea and vomiting;Incidence of postoperative bradycardia;Time to extubation;Duration of PACU stay;The time of first exhaust and defecation and the time of first ambulation;Length of Postoperative Hospital Stay;Postoperative Pain Score;

Countries

China

Contacts

Public ContactGuixiang Zhang

Nanjing Drum Tower Hospital Group Suqian Hospital

920204261@qq.com+86 180 3699 8872

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026